Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

This study is observing how people with ALK-positive advanced lung adenocarcinoma respond to iruplinalkib — a newer targeted therapy — after their cancer stopped responding to or they could not tolerate lorlatinib, a previous generation ALK inhibitor. **You may be eligible if...** - You are 18 or older - You have advanced lung adenocarcinoma with an ALK gene rearrangement confirmed by a validated test - You were previously treated with lorlatinib and your cancer progressed or you had intolerance to it - You have started treatment with iruplinalkib in a real-world clinical setting - You have at least one evaluable tumor lesion and adequate medical records available **You may NOT be eligible if...** - You never actually received iruplinalkib (or took it for less than one week without a medical reason) - Your cancer is of a different histological type than adenocarcinoma - You are currently enrolled in another interventional clinical trial with an anti-cancer drug - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.